SG11202100642UA - Cd80 extracellular domain fc fusion protein dosing regimens - Google Patents

Cd80 extracellular domain fc fusion protein dosing regimens

Info

Publication number
SG11202100642UA
SG11202100642UA SG11202100642UA SG11202100642UA SG11202100642UA SG 11202100642U A SG11202100642U A SG 11202100642UA SG 11202100642U A SG11202100642U A SG 11202100642UA SG 11202100642U A SG11202100642U A SG 11202100642UA SG 11202100642U A SG11202100642U A SG 11202100642UA
Authority
SG
Singapore
Prior art keywords
fusion protein
extracellular domain
dosing regimens
protein dosing
regimens
Prior art date
Application number
SG11202100642UA
Inventor
Sandeep P Inamdar
Kristen Pierce
Hong Xiang
Susannah D Barbee
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of SG11202100642UA publication Critical patent/SG11202100642UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG11202100642UA 2018-08-29 2019-08-28 Cd80 extracellular domain fc fusion protein dosing regimens SG11202100642UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862724443P 2018-08-29 2018-08-29
US201962818462P 2019-03-14 2019-03-14
PCT/US2019/048560 WO2020047087A1 (en) 2018-08-29 2019-08-28 Cd80 extracellular domain fc fusion protein dosing regimens

Publications (1)

Publication Number Publication Date
SG11202100642UA true SG11202100642UA (en) 2021-03-30

Family

ID=68063025

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100642UA SG11202100642UA (en) 2018-08-29 2019-08-28 Cd80 extracellular domain fc fusion protein dosing regimens

Country Status (12)

Country Link
US (1) US20210340214A1 (en)
EP (1) EP3843767A1 (en)
JP (1) JP2021535083A (en)
KR (1) KR20210049814A (en)
CN (1) CN112543642A (en)
AU (1) AU2019333059A1 (en)
BR (1) BR112021003758A2 (en)
CA (1) CA3108064A1 (en)
IL (1) IL281003A (en)
MX (1) MX2021002208A (en)
SG (1) SG11202100642UA (en)
WO (1) WO2020047087A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180306A (en) 2015-11-02 2018-10-16 Five Prime Therapeutics Inc CD80 EXTRACELLULAR DOMAIN POLIPEPTIDES AND ITS USE IN CANCER TREATMENT
CN110546509A (en) 2017-04-28 2019-12-06 戊瑞治疗有限公司 Methods of treatment with CD80 extracellular domain polypeptides
WO2021092084A1 (en) * 2019-11-04 2021-05-14 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
TW202146437A (en) * 2020-02-26 2021-12-16 美商戊瑞治療有限公司 Cd80 extracellular domain fc fusion protein therapy
CR20220606A (en) * 2020-06-03 2023-01-23 Boehringer Ingelheim Int Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100976076B1 (en) 2003-05-22 2010-08-17 아보트 러보러터리즈 Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2005108432A2 (en) * 2004-03-30 2005-11-17 Indiana University Research & Technology Corporation Cd80 (b7-1) binding peptides and uses thereof
CA2614039C (en) * 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
EP1931697B1 (en) * 2005-09-28 2010-09-15 ZymoGenetics, Inc. Il-17a and il-17f antagonists and methods of using the same
EP2612868B1 (en) * 2007-11-01 2018-08-15 Astellas Pharma Inc. Immunosuppressive polypeptides and nucleic acids
KR20110074850A (en) * 2008-08-25 2011-07-04 앰플리뮨, 인크. Pd-1 antagonists and methods of use thereof
LT3283508T (en) * 2015-04-17 2021-07-12 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CR20180306A (en) * 2015-11-02 2018-10-16 Five Prime Therapeutics Inc CD80 EXTRACELLULAR DOMAIN POLIPEPTIDES AND ITS USE IN CANCER TREATMENT
CN110352245A (en) * 2016-10-20 2019-10-18 高山免疫科学股份有限公司 Variant immune modulator and engineering cell therapy can be secreted
CN110546509A (en) * 2017-04-28 2019-12-06 戊瑞治疗有限公司 Methods of treatment with CD80 extracellular domain polypeptides

Also Published As

Publication number Publication date
JP2021535083A (en) 2021-12-16
MX2021002208A (en) 2021-05-14
EP3843767A1 (en) 2021-07-07
IL281003A (en) 2021-04-29
BR112021003758A2 (en) 2021-05-25
CA3108064A1 (en) 2020-03-05
KR20210049814A (en) 2021-05-06
US20210340214A1 (en) 2021-11-04
AU2019333059A1 (en) 2021-03-18
WO2020047087A1 (en) 2020-03-05
CN112543642A (en) 2021-03-23

Similar Documents

Publication Publication Date Title
IL281003A (en) Cd80 extracellular domain fc fusion protein dosing regimens
MA46534A (en) FC HETERODIMERIC FUSION PROTEIN IL15 / IL15R
IL292222A (en) Chimeric antigen receptors targeting her2
MA51291A (en) MODIFIED IL-2 FC FUSION PROTEINS
EP3313373A4 (en) A stable liquid formulation of fusion protein with igg fc domain
ZA201701810B (en) Sirp-alpha immunoglobulin fusion proteins
IL258527A (en) Anti-cd30 chimeric antigen receptors
EP3256496A4 (en) Chimeric antigen receptors
IL246997A0 (en) Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
EP3189148A4 (en) Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
EP3233920A4 (en) Single chain fc fusion proteins
IL270896A (en) Chimeric antigen receptors targeting flt3
EP3528851A4 (en) Cereblon-based heterodimerizable chimeric antigen receptors
EP3122371A4 (en) Fgf23 fusion proteins
EP3344295A4 (en) Anti-sialyl tn chimeric antigen receptors
EP3134434A4 (en) Kappa/lambda chimeric antigen receptors
EP3147298A4 (en) Pd-l1 fusion protein and use thereof
DK3107562T3 (en) P97-IDS FUSION PROTEIN
IL274124A (en) Protein engineered extracellular vesicles
ZA201808128B (en) Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
EP3199555A4 (en) Recombinant fusion protein formulation
EP3199179A4 (en) Recombinant fusion protein formulation
ZA202003845B (en) Fusion proteins
ZA202102533B (en) Fusion protein
EP3585403A4 (en) Tim3-binding chimeric antigen receptors